Related Experiment Videos
Case report: congenital retroperitoneal fibrosarcoma
C M Hamm1, A Pyesmany, L Resch
1Department of Hematology/Oncology, IWK Children's Hospital, Dalhousie University, Halifax, Nova Scotia, Canada.
Medical and Pediatric Oncology
|January 1, 1997
Summary
This case study details a congenital retroperitoneal fibrosarcoma in an infant. Despite complications, surgical debulking followed by chemotherapy led to clinical remission, highlighting chemotherapy's growing role in pediatric fibrosarcoma treatment.
Area of Science:
- Pediatric Oncology
- Surgical Oncology
- Medical Genetics
Background:
- Congenital retroperitoneal fibrosarcoma is a rare pediatric malignancy.
- Optimal treatment strategies for pediatric fibrosarcomas are evolving.
Observation:
- A 17-day-old male presented with a large retroperitoneal fibrosarcoma.
- Surgical debulking (80% removal) was complicated by significant blood loss and cardiac arrhythmias.
- Postoperative chemotherapy resulted in severe hepatic, hematological, and gastrointestinal toxicity.
Findings:
- The patient achieved clinical remission after 9 months of follow-up.
- Literature review indicates a shift towards increased use of chemotherapy in pediatric fibrosarcoma management.
- Chemotherapy is increasingly utilized both preoperatively and postoperatively.
Implications:
- This case underscores the complex management of congenital retroperitoneal fibrosarcoma in neonates.
- The findings support the integration of chemotherapy into multimodal treatment protocols for pediatric fibrosarcoma.
- Further research into optimizing chemotherapy regimens to mitigate toxicity in infants is warranted.